ES2179207T3 - Formulaciones de hierro dextrano. - Google Patents

Formulaciones de hierro dextrano.

Info

Publication number
ES2179207T3
ES2179207T3 ES96930686T ES96930686T ES2179207T3 ES 2179207 T3 ES2179207 T3 ES 2179207T3 ES 96930686 T ES96930686 T ES 96930686T ES 96930686 T ES96930686 T ES 96930686T ES 2179207 T3 ES2179207 T3 ES 2179207T3
Authority
ES
Spain
Prior art keywords
dextran iron
iron formulations
dextran
formulations
oxihidr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96930686T
Other languages
English (en)
Inventor
Richard P Lawrence
Ralf A Lange
Mary Jane Helenek
Chin Wu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
American Regent Inc
Original Assignee
Luitpold Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Luitpold Pharmaceuticals Inc filed Critical Luitpold Pharmaceuticals Inc
Application granted granted Critical
Publication of ES2179207T3 publication Critical patent/ES2179207T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

COMPOSICIONES DE DEXTRANO - OXIHIDR - XIDO FERRICO PARA EL TRATAMIENTO DE LA DEFICIENCIA DE HIERRO, QUE POSEEN PARTICULAS ELIPSOIDALES CON UN RANGO PREFERIDO DE PESO MOLECULAR DE ALREDEDOR DE 250.000 A 300.000 DALTONS.
ES96930686T 1995-09-29 1996-08-29 Formulaciones de hierro dextrano. Expired - Lifetime ES2179207T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/536,984 US5624668A (en) 1995-09-29 1995-09-29 Iron dextran formulations

Publications (1)

Publication Number Publication Date
ES2179207T3 true ES2179207T3 (es) 2003-01-16

Family

ID=24140716

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96930686T Expired - Lifetime ES2179207T3 (es) 1995-09-29 1996-08-29 Formulaciones de hierro dextrano.

Country Status (11)

Country Link
US (1) US5624668A (es)
EP (1) EP0855913B1 (es)
JP (1) JP3471363B2 (es)
AT (1) ATE218875T1 (es)
AU (1) AU702691B2 (es)
CA (1) CA2184551C (es)
DE (1) DE69621813T2 (es)
DK (1) DK0855913T3 (es)
ES (1) ES2179207T3 (es)
PT (1) PT855913E (es)
WO (1) WO1997011711A1 (es)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6306384B1 (en) * 1996-10-01 2001-10-23 E-L Management Corp. Skin battery cosmetic composition
DK172860B1 (da) * 1998-03-25 1999-08-16 Pharmacosmos Holding As Jerndextranforbindelse til anvendelse som komponent i et terapeutisk middel til forebyggelse af eller behandling af jernman
US6610206B1 (en) 1998-10-20 2003-08-26 Advanced Renal Technologies Buffered compositions for dialysis
US7670491B2 (en) * 1998-10-20 2010-03-02 Advanced Renal Technologies Buffered compositions for dialysis
DK173138B1 (da) 1998-11-20 2000-02-07 Pharmacosmos Holding As Fremgangsmåde til fremstilling af en jerndextranforbindelse, jerndextranforbindelse fremstillet efter fremgangsmåden, farma
DK1218039T3 (da) * 1999-09-22 2009-06-15 Advanced Renal Technologies Anvendelse af dialysat med höjt citratindhold
US6929954B2 (en) 2000-11-02 2005-08-16 Chromaceutical Advanced Technologies, Inc. Method for producing purified hematinic iron-saccharidic complex and product produced
EP1330226A4 (en) * 2000-11-02 2005-11-23 Chromaceutical Advanced Tech METHOD FOR PRODUCING A CLEANED HEMATIN IRON SACCHARIDE COMPLEX AND PRODUCT MANUFACTURED
EP1719495A3 (en) * 2000-11-02 2007-05-02 Chromaceutical Advanced Technologies, Inc. Method for producing purified hematinic iron-saccharidic complex and product produced
US6825032B2 (en) * 2001-05-14 2004-11-30 Sigma-Aldrich Co. High capacity assay platforms
US7169359B2 (en) * 2002-08-26 2007-01-30 Luitpold Pharmaceuticals, Inc. Bioequivalence test for iron-containing formulations
JP4408807B2 (ja) * 2002-08-26 2010-02-03 ヴァイフォー（インターナショナル）アーゲー 鉄含有処方の生物学的等価性試験
DE10249552A1 (de) 2002-10-23 2004-05-13 Vifor (International) Ag Wasserlösliche Eisen-Kohlenhydrat-Komplexe, deren Herstellung und diese enthaltende Arzneimittel
US7390472B1 (en) * 2002-10-29 2008-06-24 Nei Corp. Method of making nanostructured lithium iron phosphate—based powders with an olivine type structure
US20040161852A1 (en) * 2003-02-14 2004-08-19 Anderson Christopher G. Method of assaying an Fe-Sugar complex
US20060116349A1 (en) * 2003-03-14 2006-06-01 Luitpold Pharmaceuticals, Inc. Methods and compositions for administration of iron for the treatment of restless leg syndrome
US7964568B2 (en) * 2003-05-30 2011-06-21 Chromaceutical Advanced Technologies, Inc. Synthesis of high molecular weight iron-saccharidic complexes
US7449196B2 (en) * 2004-07-09 2008-11-11 Robert Sabin Anti tumor compositions and methods of use
NZ552451A (en) 2004-07-09 2010-07-30 Robert Sabin Compositions and methods of use for treatment of mammalian diseases
EP3081219A1 (en) 2006-01-06 2016-10-19 Luitpold Pharmaceuticals, Inc. Methods and compositions for administration of iron
AU2013206429B2 (en) * 2006-01-06 2016-04-28 Vifor (International) Ag Methods and compositions for administration of iron
AU2016205002C1 (en) * 2006-01-06 2020-09-24 Vifor (International) Ag Methods and compositions for administration of iron
US20080081051A1 (en) * 2006-09-28 2008-04-03 Robert Sabin Method of manufacturing anti-tumor and anti-viral compositions
US20080132465A1 (en) * 2006-12-05 2008-06-05 Vincent Windisch Apparatus and method for isolating iron components from serum
CN105380936A (zh) * 2006-12-12 2016-03-09 味之素株式会社 铁代谢改善剂
TWI468167B (zh) 2007-11-16 2015-01-11 威佛（國際）股份有限公司 藥學組成物
MX2011009936A (es) 2009-03-25 2011-10-06 Pharmacosmos Holding As Un compuesto de oligosacarido de hierro estable.
US8058076B2 (en) * 2009-03-31 2011-11-15 Astron Research Limited In-vitro method for testing bioequivalence of iron-sucrose formulation
PT104879B (pt) * 2009-12-10 2012-10-17 Univ Do Minho Hidrogel de dextrino para aplicações biomédicas
CA2849926C (en) 2011-10-13 2020-07-21 Vidasym, Inc. Iron-fiber composition, preparation and uses thereof
CN103044571A (zh) * 2011-10-13 2013-04-17 天津中敖生物科技有限公司 右旋糖酐铁原料药及其制备方法
CN109497565B (zh) 2013-03-08 2021-10-26 上海礼邦医药科技有限公司 金属离子-功能性纤维组分络合物组合物、其制备及用途
US9370202B2 (en) 2013-03-15 2016-06-21 LG Bionano, LLC Encapsulated metal ion nanoclusters
WO2018198135A1 (en) * 2017-04-26 2018-11-01 Mylan Laboratories Ltd. Improved process for the preparation of iron complex
SG11202001594TA (en) 2017-09-11 2020-03-30 Pharmacosmos Holding As Iron complex compounds for therapeutic use
CA3084677A1 (en) * 2017-12-07 2019-06-13 Commonwealth Scientific And Industrial Research Organisation Sugar reduced products and method of producing thereof
SI3930686T1 (sl) 2019-02-28 2023-11-30 Renibus Therapeutics, Inc. Novi železovi sestavki ter metode njihove izdelave in uporabe
CN113567370A (zh) * 2021-07-23 2021-10-29 广西南宁市桃源兽药厂 一种用于检测右旋糖酐铁注射液中糖酐含量的方法
CN116712455B (zh) * 2023-06-30 2024-04-05 重庆汉佩生物科技有限公司 一种氟苯尼考与葡庚糖酐铁的组合物

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE24642E (en) * 1959-04-28 Therapeutic preparations of iron
US2820740A (en) * 1953-02-27 1958-01-21 Benger Lab Ltd Therapeutic preparations of iron
US2885393A (en) * 1956-02-24 1959-05-05 R K Laros Company Dextran-iron complex and process for making same
US3697502A (en) * 1969-11-03 1972-10-10 Christensen Henry M Method of making iron dextran-preparations
US3686397A (en) * 1970-05-18 1972-08-22 Mueller Arthur Parenteral iron preparations
US3908004A (en) * 1970-05-20 1975-09-23 C L Basingstoke Limited Process for making injectable iron compositions for treating iron-deficiency anemia
JPS5913521B2 (ja) * 1975-06-19 1984-03-30 メイトウサンギヨウ カブシキガイシヤ 磁性酸化鉄・デキストラン複合体の製造法
US4180567A (en) * 1977-09-02 1979-12-25 Pharmachem Corporation Iron preparations and methods of making and administering the same
DE3026868C2 (de) * 1980-07-16 1986-03-13 Laboratorien Hausmann AG, St. Gallen Verfahren zur Herstellung von Eisen(III)hydroxid-Dextran-Komplexen und sie enthaltende pharmazeutische sterile wäßrige Lösung
US4454773A (en) * 1981-11-06 1984-06-19 Texaco Inc. Time interval automatic well multi-phase fluid sampler
US4452773A (en) * 1982-04-05 1984-06-05 Canadian Patents And Development Limited Magnetic iron-dextran microspheres
JPS58199018A (ja) * 1982-05-18 1983-11-19 Nippon Denso Co Ltd 電気的加熱手段を有する排気ガス微粒子浄化装置
US4659697A (en) * 1983-05-20 1987-04-21 Kentaro Tanaka Antianaemic composition and a process for producing the same
US4788281A (en) * 1984-01-04 1988-11-29 Tosoni Anthony L Dextran hexonic acid derivative, ferric hydroxide complex and method manufacture thereof
DE3422249A1 (de) * 1984-06-15 1985-12-19 Pfeifer & Langen, 5000 Köln Wasserloesliches eisendextran und verfahren zu seiner herstellung
US5248492A (en) * 1986-07-03 1993-09-28 Advanced Magnetics, Inc. Low molecular weight carbohydrates as additives to stabilize metal oxide compositions
US5336506A (en) * 1986-07-03 1994-08-09 Advanced Magnetics Inc. Targeting of therapeutic agents using polysaccharides
US5102652A (en) * 1986-07-03 1992-04-07 Advanced Magnetics Inc. Low molecular weight carbohydrates as additives to stabilize metal oxide compositions
US5118513A (en) * 1987-07-02 1992-06-02 The Procter & Gamble Company Method for enhancing bioavailability of iron-calcium mineral supplements
US5354350A (en) * 1993-12-14 1994-10-11 The Vigoro Corporation Citrate soluble slow release iron humate

Also Published As

Publication number Publication date
EP0855913A1 (en) 1998-08-05
EP0855913B1 (en) 2002-06-12
DE69621813T2 (de) 2003-01-23
PT855913E (pt) 2002-11-29
CA2184551C (en) 2001-11-27
AU702691B2 (en) 1999-03-04
JP3471363B2 (ja) 2003-12-02
DK0855913T3 (da) 2002-10-07
AU6964796A (en) 1997-04-17
ATE218875T1 (de) 2002-06-15
JPH11512706A (ja) 1999-11-02
CA2184551A1 (en) 1997-03-30
WO1997011711A1 (en) 1997-04-03
US5624668A (en) 1997-04-29
EP0855913A4 (en) 1999-01-20
DE69621813D1 (de) 2002-07-18

Similar Documents

Publication Publication Date Title
ATE218875T1 (de) Eisen-dextran formulierungen
ES2180899T3 (es) Dihidrato d de olanzapina.
DK0960107T3 (da) 6-Thiosubstituerede paclitaxeler
ES2192273T3 (es) Procedimiento para producir compuestos de ecteinascidina.
IL133890A0 (en) Trifluoroacetyl copolymer - 1
ID23374A (id) Halogenopirimidin
FR2774753B1 (fr) Installation de distillation d'air comprenant plusieurs unites de distillation cryogenique de meme nature
ES2162067T3 (es) Composicion de vacuna anti-haemophilus influenzae de tipo b que comprende poli-ribosil-ribitol-fosfato y su procedimiento de preparacion.
AR016981A2 (es) Polipeptidos sinteticos
BG99177A (bg) Нови 7 бета-заместени-4-аза-5 алфа-холестанони като инхибитори на 5 алфа-редуктаза
ES2179138T3 (es) Poliisocianatos que presentan grupos alofanato basados en difenilmetanodiisocianato con grupos isocianato predominante o completamente bloqueados.
MX9203971A (es) Proceso para incrementar el peso molecular de poliamida.
DK1012186T3 (da) Keratinocyt-vækstfaktorer og anvendelser deraf
IL128500A (en) SUBSTITUTED 1,2,3,4-TETRAHYDRO-2-DIBENZOFURANAMINES AND 2-AMINOCYCLOHEPTA[b] BENZOFURANS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
BG100248A (bg) Инхибитори на скваленсинтетаза
EP1073447A4 (en) N1-MODIFIED GLYCOPEPTIDES
DE69614552D1 (de) MODIFIZIERTE ALPHA-D-GLCP-(1,2)-ALPHA-D-Glcp-(1,3)-ALPHA-D-Glcp-ANALOGE
ES2112978T3 (es) Composicion de polimeros para aplicaciones medicas.
ES2116241B1 (es) Composicion para la obtencion de un aguardiente.
ES2116946B1 (es) Composicion para la obtencion de un aguardiente.
ES1025005Y (es) "nueva disposicion para la union de cuerpos con pisos de calzados."
ES2077358T3 (es) N-alquil-3-fenil-3-(2-alquiltiofenoxi)propilaminas.
IT236761Y1 (it) Serratura per mobili o simili ad elevata semplicita' di installazione
UA30250A (uk) Антиоксидантний засіб
ES2128272A1 (es) Composicion de un producto desodorante de aplicacion para los pies.